Human papilloma computer virus (HPV) is considered to be responsible for a large portion of vaginal and vulvar carcinomas and the BIIB-024 p53 codon 72 polymorphism has been implicated in susceptibility to malignancy induced by this computer virus but with contradicting results. (version 13 StatSoft Inc. Tulsa USA). Results Patient data and polymorphism Sixty-six samples from the vaginal cohort and 123 samples from your vulvar cohort were analyzed by focusing on the BIIB-024 polymorphic variants arginine and proline of codon 72 in p53. In the vaginal cohort BIIB-024 53.0% (35 instances) were arg/arg 37.9% (25 cases) were arg/pro and 4.5% (3 cases) were pro/pro. In the vulvar cohort 55.3% (68 cases) were arg/arg 35.8% (44 cases) were arg/pro and 4.1% (5 instances) were pro/pro (Table?1). Three samples (4.5%) from your vaginal cohort and 6 samples (4.9%) from your vulvar cohort were not classifiable and were placed in separate BIIB-024 organizations marked as “undefined.” Table?1 Prevalence of the polymorphic variants of the p53 codon 72 in vaginal and vulvar carcinomas The mean age of individuals in the vaginal cohort with arg/arg tumors was 70.1?years (SD 12.4?years) for arg/pro genotype tumors 68.5?years (SD 11.9?years) and for pro/pro genotype tumors 65.7?years (SD 18.1?years). These variations were not significant. In vulvar carcinoma the mean age at analysis of individuals with arg/arg genotype tumors was 69.7?years (SD 14.5?years) for pro/arg tumors 73.8?years (SD 12.0?years) and for pro/pro genotype tumors 68.8?years (SD 11.0?years). No significant variations were found. HPV tumor and association characteristics The vaginal cohort contains 35 HPV-positive situations and 31 HPV-negative situations. The arg/arg polymorphism (57.1%) was more prevalent compared to the arg/pro version (40.0%) in HPV-positive tumors and the opposite was seen in HPV-negative tumors (42.9 vs. 60.0%). The difference was not statistically significant (Pearson test test; p?=?0.015) larger at analysis (mean diameter 36?mm SD 23?mm) than tumors with arg/pro or pro/pro genotypes (mean 25?mm SD 14?mm) in the vulvar cohort. Data on tumor size at analysis were only evaluable on 84 out of 130 instances (64.6%). Type of histology was not significantly associated with polymorphism in the vaginal cohort (Table?2). In the vulvar cohort arg/arg genotype was more frequent (73.7%) in tumors of mixed type than in tumors of basaloid or keratinizing type (55.1%) however not significant (Pearson χ 2 p?=?0.133) (Table?2). Clinical end result Primary cure rate Vaginal carcinomas The primary cure rate of the complete series was 53 out of 66 (80.3%) instances. Among tumors achieving primary treatment (total remission) in the vaginal group the arg/arg genotype was significantly (Pearson χ 2 p?=?0.023) more common (66.0%) than in tumors not achieving main treatment (30.8%). Vulvar carcinomas The primary cure rate of the complete series was 116 out of 123 (88.6%) instances. The primary cure was 91.2% in the arg/arg group and 86.4% in the arg/pro genotype group (Pearson χ 2 p?=?0.421). Tumor recurrences Vaginal carcinomas Arg/arg genotype was more common (15/21 71.4%) in tumors with recurrences (all types and sites) than in tumors with no recurrences (20/42 47.6%) (Pearson χ 2 p?=?0.073). In BIIB-024 tumors with distant recurrences this difference was more pronounced (10/11 90.9% vs. 25/52 48.1%) and highly statistically significant (Pearson χ 2 p?=?0.009). Vulvar carcinomas In the vulvar cohort the overall recurrence rate was 31/68 (45.6%) among tumors with arg/arg genotype and 17/49 (34.7%) in tumors with Tmprss11d arg/pro or pro/pro genotype (Pearson χ 2 p?=?0.237). Local vulvar recurrences were related in tumors with arg/arg genotype (16/68 23.5%) and in tumors with arg/pro or pro/pro genotype (12/49 24.5%) (Pearson χ 2 p?=?0.904). Inguinal lymph node recurrences were recorded in 11/68 (16.2%) tumors with arg/arg genotype and in 6/49 (12.2%) tumors with arg/pro or pro/pro genotype (Pearson χ 2 p?=?0.552). Distant recurrences were recorded in 4/68 (5.9%) tumors with arg/arg genotype and in 4/49 (8.2%) tumors with pro/arg or pro/pro genotype (Pearson χ 2.